厄洛替尼致间质性肺病  

Interstitial lung disease due to erlotinib

作　　者：章俊强[1] 徐飞[1] 徐晓玲[1] 周倩倩[1] 

机构地区：[1]安徽省立医院呼吸科,合肥230000

出　　处：《药物不良反应杂志》2017年第5期377-378,共2页Adverse Drug Reactions Journal

摘　　要：1例60岁表皮生长因子受体（EGFR）基因19外显子缺失突变型小细胞肺癌（T4N3M1b,广泛期）男性患者接受酪氨酸激酶抑制剂厄洛替尼靶向治疗（150 mg口服、1次/d）.用药28 d后患者感胸闷加重,复查胸部CT示双肺间质性改变,考虑为厄洛替尼所致间质性肺病.停用厄洛替尼并给予甲泼尼龙抗炎和对症支持治疗,但患者症状未缓解,肿瘤进展.停用厄洛替尼后33 d患者死亡.A 60-years-old male patient with epidermal growth factor receptor gene exon 19 deletion mutant small cell lung cancer（T4N3M1b,exensive disease）received tyrosine kinase inhibitor erlotinib 150 mg orally once daily. On day 28 of medication,the patient felt aggravated chest distress. The result of reexamination of chest CT showed interstitial changes in lungs. He was diagnosed as interstitial lung disease due to erlotinib. Erlotinib was stopped. The patient received methylprednisolone for anti-inflammatory and symptomatic treatment. However,his symptoms were not relieved and the tumor progressed. The patient died on day 33 of erlotinib withdrawal.

关 键 词：小细胞肺癌 盐酸厄洛替尼 肺疾病 间质性 

分 类 号：R979.1[医药卫生—药品]